ASX RELEASE

Resignation of Non-Executive Director: Dr John Chiplin

Melbourne, Australia, 27 September 2018: Sienna Cancer Diagnostics Ltd, (ASX:SDX) ("Sienna" or "the Company"), a medical technology company developing and commercialising innovative cancer related tests, advises that Dr John Chiplin is to resign from the board of the Company on 30 September 2018. Dr Chiplin has been a Non-Executive Director at Sienna since early 2016.

Dr Geoff Cumming, Chairman of Sienna thanked John for his service: "John has been a valuable and respected member of the Sienna Board over the last few years, providing extensive sector knowledge and experience."

Dr Chiplin said: "I'm proud to have been part of the team which guided Sienna through its listing on the ASX. The Company has built strong foundations based on great technology and I look forward to observing its continued success."

The Board and management at Sienna thank John for his contribution and wish him well in his future endeavours.

ENDS.

For further information, please contact:

Matthew Hoskin, CEO
Sienna Cancer Diagnostics
mhoskin@siennadiagnostics.com.au
+61 3 8288 2141

Kyahn Williamson or Lauren Nowak
WE Buchan
sienna@we-buchan.com
+61 3 8866 1200

About Sienna Cancer Diagnostics

Sienna Cancer Diagnostics Ltd. is an Australian medical technology company, with operations in the United States, Europe and Australia. Sienna's strengths lie in identifying novel technologies then developing and commercialising them to satisfy an unmet clinical / market need. The Company has demonstrated the utility of its product with the help of its global clinical partners. Sienna's primary platform is the detection of the biomarker telomerase, which is found in nearly all epithelial cancers, and was the subject of a Nobel Prize in 2009. Telomerase is well recognised for being used by 85% of cancers to enable immortal cell replication.

The FDA listing of Sienna's first IVD in the United States, and CE marking / IVD registration in Europe and Australia, means the assay can be used for clinical diagnostic purposes by pathology laboratories. Clinical pathology laboratories in those regions may purchase the product for use as an in vitro diagnostic test for the presence of hTERT, a component of telomerase.

Forward Looking Statements

This announcement may contain forward-looking statements, which include all matters that are not historical facts. These forward-looking statements speak only as at the date of this announcement. These statements, by their nature, are subject to a number of known and unknown risks and uncertainties that could cause the actual results, performances and achievements to differ materially from any expected future results, performance or achievements expressed or implied by forward-looking statements. Without limitation, indications of, and guidance on, future earnings and financial position and performance are examples of forward-looking statements. No representation, warranty or assurance (express or implied) is given or made by Sienna that the forward-looking statements contained in this announcement are accurate, complete, reliable, or adequate or that they will be achieved or prove to be correct. Except for any statutory liability which cannot be excluded, each of Sienna, its related companies and their respective directors, employees and advisers expressly disclaim any responsibility for the accuracy or completeness of the forward-looking statements and exclude all liability whatsoever (including negligence) for any direct or indirect loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.